{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T04:27:21Z","timestamp":1786768041724,"version":"build-2736575974"},"reference-count":46,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Annals of Neurology"],"abstract":"\n Objective<\/jats:title>\n \n Recent studies suggest that combining plasma phosphorylated tau (p\u2010tau) with\n \u03b2<\/jats:italic>\n \u2010amyloid (A\n \u03b2<\/jats:italic>\n ) may improve diagnosis accuracy for Alzheimer's disease (AD). However, the cross\u2010sectional and longitudinal concordance of these markers with A\n \u03b2<\/jats:italic>\n positron emission tomography (PET) positivity remains incompletely understood. This study aimed to evaluate the diagnostic performance of plasma p\u2010tau, alone and in combination with plasma A\n \u03b2<\/jats:italic>\n , in AD.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n We included 326 participants from the Alzheimer's Disease Neuroimaging Initiative and 357 Chinese older adults from the Greater\u2010Bay\u2010Area Healthy Aging Brain Study who underwent A\n \u03b2<\/jats:italic>\n \u2010PET imaging. Longitudinal data were available for 285 Alzheimer's Disease Neuroimaging Initiative participants. Plasma p\u2010tau181, p\u2010tau217, A\n \u03b2<\/jats:italic>\n 42, and A\n \u03b2<\/jats:italic>\n 40 were measured on different analytical platforms. Diagnostic performance for A\n \u03b2<\/jats:italic>\n \u2010PET positivity was assessed using a two\u2010cutoff approach.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Combining plasma p\u2010tau with A\n \u03b2<\/jats:italic>\n 42 or the A\n \u03b2<\/jats:italic>\n 42\/40 ratio reduced the intermediate zone. Notably, p\u2010tau217\/A\n \u03b2<\/jats:italic>\n 42 showed stronger agreement with A\n \u03b2<\/jats:italic>\n \u2010PET positivity than p\u2010tau217 alone. Among individuals classified as p\u2010tau217\/A\n \u03b2<\/jats:italic>\n 42 positive but p\u2010tau217 intermediate, 57.1 to 83.3% were A\n \u03b2<\/jats:italic>\n \u2010PET positive. Longitudinally, most Stable Positive (88.0\u201396.1%) and Stable Negative (89.4\u201390.9%) cases defined by p\u2010tau217 or p\u2010tau217\/A\n \u03b2<\/jats:italic>\n 42 were A\n \u03b2<\/jats:italic>\n \u2010PET positive and A\n \u03b2<\/jats:italic>\n \u2010PET negative, respectively. Critically, 69.7 to 75.8% of Non\u2010positive to Positive cases defined by p\u2010tau217\/A\n \u03b2<\/jats:italic>\n 42 were A\n \u03b2<\/jats:italic>\n \u2010PET positive.\n <\/jats:p>\n <\/jats:sec>\n \n Interpretation<\/jats:title>\n \n These findings provide novel insights into the cross\u2010sectional and longitudinal diagnostic performance of plasma p\u2010tau217\/A\n \u03b2<\/jats:italic>\n 42 in AD. To be specific, plasma p\u2010tau217\/A\n \u03b2<\/jats:italic>\n 42 can reduce the intermediate zone and improve agreement with A\n \u03b2<\/jats:italic>\n \u2010PET positivity, and longitudinal p\u2010tau217\/A\n \u03b2<\/jats:italic>\n 42 monitoring is particularly informative for identifying A\n \u03b2<\/jats:italic>\n \u2010PET\u2013positive patients who were p\u2010tau217\/A\n \u03b2<\/jats:italic>\n 42 negative or intermediate at baseline and were misclassified as low risk of AD. ANN NEUROL 2026\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/ana.78322","type":"journal-article","created":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T03:46:08Z","timestamp":1786765568000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cross\u2010Sectional and Longitudinal Diagnostic Performance of Plasma p\u2010tau217 and p\u2010tau217\/A\u03b242 in Alzheimer's Disease"],"prefix":"10.1002","author":[{"given":"Mingxing","family":"Jiang","sequence":"first","affiliation":[{"name":"Shenzhen Medical Academy of Research and Translation Shenzhen China"},{"name":"Westlake University Hangzhou China"},{"name":"Institute of Neurological and Psychiatric Disorders Shenzhen Bay Laboratory Shenzhen China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoyu","family":"Lan","sequence":"additional","affiliation":[{"name":"Institute of Neurological and Psychiatric Disorders Shenzhen Bay Laboratory Shenzhen China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Zhu","sequence":"additional","affiliation":[{"name":"Institute of Neurological and Psychiatric Disorders Shenzhen Bay Laboratory Shenzhen China"},{"name":"School of Biology and Biological Engineering South China University of Technology Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laihong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Institute of Neurological and Psychiatric Disorders Shenzhen Bay Laboratory Shenzhen China"},{"name":"School of Life Science and Technology Harbin Institute of Technology Harbin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anqi","family":"Li","sequence":"additional","affiliation":[{"name":"Institute of Neurological and Psychiatric Disorders Shenzhen Bay Laboratory Shenzhen China"},{"name":"Division of Life Science The Hong Kong University of Science and Technology Hong Kong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengbo","family":"He","sequence":"additional","affiliation":[{"name":"Institute of Neurological and Psychiatric Disorders Shenzhen Bay Laboratory Shenzhen China"},{"name":"School of Life Science and Technology Harbin Institute of Technology Harbin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalin","family":"Zhu","sequence":"additional","affiliation":[{"name":"Institute of Neurological and Psychiatric Disorders Shenzhen Bay Laboratory Shenzhen China"},{"name":"Division of Life Science The Hong Kong University of Science and Technology Hong Kong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhou","sequence":"additional","affiliation":[{"name":"Institute of Neurological and Psychiatric Disorders Shenzhen Bay Laboratory Shenzhen China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liang","sequence":"additional","affiliation":[{"name":"Institute of Neurological and Psychiatric Disorders Shenzhen Bay Laboratory Shenzhen China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Gao","sequence":"additional","affiliation":[{"name":"Institute of Neurological and Psychiatric Disorders Shenzhen Bay Laboratory Shenzhen China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Sun","sequence":"additional","affiliation":[{"name":"Institute of Neurological and Psychiatric Disorders Shenzhen Bay Laboratory Shenzhen China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Cai","sequence":"additional","affiliation":[{"name":"Institute of Neurological and Psychiatric Disorders Shenzhen Bay Laboratory Shenzhen China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Medical Imaging Peking University Shenzhen Hospital Shenzhen China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuhui","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurology Peking University Shenzhen Hospital Shenzhen China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Shi","sequence":"additional","affiliation":[{"name":"Neurology Medicine Center The Seventh Affiliated Hospital, Sun Yat\u2010sen University Shenzhen China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Liu","sequence":"additional","affiliation":[{"name":"Institute of Neurological and Psychiatric Disorders Shenzhen Bay Laboratory Shenzhen China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology Shenzhen University of Advanced Technology General Hospital Shenzhen China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanxun","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Medical Imaging Peking University Shenzhen Hospital Shenzhen China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine The First Affiliated Hospital of Jinan University Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Alzheimer's Disease Neuroimaging Initiative","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjie","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine Peking University Shenzhen Hospital Shenzhen China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan\u2010Jiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology and Center for Clinical Neuroscience, Daping Hospital Third Military Medical University Chongqing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2982-0865","authenticated-orcid":false,"given":"Tengfei","family":"Guo","sequence":"additional","affiliation":[{"name":"Shenzhen Medical Academy of Research and Translation Shenzhen China"},{"name":"Institute of Neurological and Psychiatric Disorders Shenzhen Bay Laboratory Shenzhen China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"crossref","first-page":"7337","DOI":"10.1016\/j.cell.2025.11.033","article-title":"The evolving landscape of Alzheimer's disease therapy: from a\u03b2 to tau","volume":"188","author":"Courade J\u2010P","year":"2025","journal-title":"Cell"},{"key":"e_1_2_9_3_1","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging\u2010Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Sperling RA","year":"2011","journal-title":"Alzheimers Dement"},{"key":"e_1_2_9_4_1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jama.2010.2008","article-title":"Use of florbetapir\u2010PET for imaging beta\u2010amyloid pathology","volume":"305","author":"Clark CM","year":"2011","journal-title":"JAMA"},{"key":"e_1_2_9_5_1","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1001\/jamaneurol.2020.0528","article-title":"Positron emission tomography imaging with [ 18 F]flortaucipir and postmortem assessment of Alzheimer disease neuropathologic changes","volume":"77","author":"Fleisher AS","year":"2020","journal-title":"JAMA Neurol"},{"key":"e_1_2_9_6_1","first-page":"e1512","article-title":"Detecting earlier stages of amyloid deposition using PET in cognitively normal elderly adults","volume":"94","author":"Guo T","year":"2020","journal-title":"Neurology"},{"key":"e_1_2_9_7_1","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1001\/jamaneurol.2025.1801","article-title":"Higher educational attainment and accelerated tau accumulation in Alzheimer disease","volume":"82","author":"Cai Y","year":"2025","journal-title":"JAMA Neurol"},{"key":"e_1_2_9_8_1","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.jalz.2018.01.010","article-title":"CSF biomarkers of Alzheimer's disease concord with amyloid\u2010\u03b2 PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts","volume":"14","author":"Hansson O","year":"2018","journal-title":"Alzheimers Dement"},{"key":"e_1_2_9_9_1","first-page":"e2075","article-title":"Association of CSF a\u03b2, amyloid PET, and cognition in cognitively unimpaired elderly adults","volume":"95","author":"Guo T","year":"2020","journal-title":"Neurology"},{"key":"e_1_2_9_10_1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13195-020-00665-8","article-title":"Normalization of CSF pTau measurement by A\u03b240 improves its performance as a biomarker of Alzheimer's disease","volume":"12","author":"Guo T","year":"2020","journal-title":"Alzheimer's Res Ther"},{"key":"e_1_2_9_11_1","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature25456","article-title":"High performance plasma amyloid\u2010\u03b2 biomarkers for Alzheimer's disease","volume":"554","author":"Nakamura A","year":"2018","journal-title":"Nature"},{"key":"e_1_2_9_12_1","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative accuracy of plasma Phospho\u2010tau217 for Alzheimer disease vs other neurodegenerative disorders","volume":"324","author":"Palmqvist S","year":"2020","journal-title":"JAMA"},{"key":"e_1_2_9_13_1","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209205","article-title":"Association of \u03b2\u2010amyloid, microglial activation, cortical thickness, and metabolism in older adults without dementia","volume":"102","author":"Cai Y","year":"2024","journal-title":"Neurology"},{"key":"e_1_2_9_14_1","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1038\/s43587-025-00904-3","article-title":"Comprehensive evaluation of plasma tau biomarkers for detecting and monitoring Alzheimer's disease in a multicenter and multiethnic aging population","volume":"5","author":"Lan G","year":"2025","journal-title":"Nat Aging"},{"key":"e_1_2_9_15_1","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/ana.26492","article-title":"Association of Presynaptic Loss with Alzheimer's disease and cognitive decline","volume":"92","author":"Lan G","year":"2022","journal-title":"Ann Neurol"},{"key":"e_1_2_9_16_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2025.102508","article-title":"Plasma growth\u2010associated protein 43 correlates with synaptic loss in Alzheimer's disease","volume":"6","author":"Lan G","year":"2025","journal-title":"Cell Rep Med"},{"key":"e_1_2_9_17_1","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.biopsych.2020.06.029","article-title":"Longitudinal cognitive and biomarker measurements support a unidirectional pathway in Alzheimer's disease pathophysiology","volume":"89","author":"Guo T","year":"2021","journal-title":"Biol Psychiatry"},{"key":"e_1_2_9_18_1","doi-asserted-by":"crossref","first-page":"7048","DOI":"10.1002\/alz.14176","article-title":"Spatial and temporal patterns of cortical mean diffusivity in Alzheimer's disease and suspected non\u2010Alzheimer's disease pathophysiology","volume":"20","author":"Sun P","year":"2024","journal-title":"Alzheimers Dement"},{"key":"e_1_2_9_19_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2025.102138","article-title":"White matter fractional anisotropy decreases precede hyperintensities in Alzheimer's disease","volume":"6","author":"Sun P","year":"2025","journal-title":"Cell Rep Med"},{"key":"e_1_2_9_20_1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"Dyck CH","year":"2023","journal-title":"N Engl J Med"},{"key":"e_1_2_9_21_1","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease","volume":"330","author":"Sims JR","year":"2023","journal-title":"JAMA"},{"key":"e_1_2_9_22_1","doi-asserted-by":"crossref","DOI":"10.1002\/alz.14528","article-title":"Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease","volume":"21","author":"Leuzy A","year":"2025","journal-title":"Alzheimers Dement"},{"key":"e_1_2_9_23_1","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association workgroup","volume":"20","author":"Jack CR","year":"2024","journal-title":"Alzheimers Dement"},{"key":"e_1_2_9_24_1","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1016\/j.neuron.2023.05.017","article-title":"Blood\u2010based biomarkers for Alzheimer's disease: current state and future use in a transformed global healthcare landscape","volume":"111","author":"Hampel H","year":"2023","journal-title":"Neuron"},{"key":"e_1_2_9_25_1","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/s41591-024-02869-z","article-title":"Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests","volume":"30","author":"Barth\u00e9lemy NR","year":"2024","journal-title":"Nat Med"},{"key":"e_1_2_9_26_1","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","article-title":"Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology","volume":"81","author":"Ashton NJ","year":"2024","journal-title":"JAMA Neurol"},{"key":"e_1_2_9_27_1","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41582-024-00977-5","article-title":"Acceptable performance of blood biomarker tests of amyloid pathology \u2014 recommendations from the global CEO initiative on Alzheimer's disease","volume":"20","author":"Schindler SE","year":"2024","journal-title":"Nat Rev Neurol"},{"key":"e_1_2_9_28_1","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/s43587-023-00471-5","article-title":"A two\u2010step workflow based on plasma p\u2010tau217 to screen for amyloid \u03b2 positivity with further confirmatory testing only in uncertain cases","volume":"3","author":"Brum WS","year":"2023","journal-title":"Nat Aging"},{"key":"e_1_2_9_29_1","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1212\/WNL.0b013e3181cb3e25","article-title":"Alzheimer's disease neuroimaging initiative (ADNI) clinical characterization","volume":"74","author":"Petersen RC","year":"2010","journal-title":"Neurology"},{"key":"e_1_2_9_30_1","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13195-024-01458-z","article-title":"Pathophysiology characterization of Alzheimer's disease in South China's aging population: for the Greater\u2010Bay\u2010area healthy Aging brain study (GHABS)","volume":"16","author":"Liu Z","year":"2024","journal-title":"Alzheimer's Res Ther"},{"key":"e_1_2_9_31_1","doi-asserted-by":"crossref","first-page":"8074","DOI":"10.1002\/alz.14315","article-title":"Head\u2010to\u2010head comparison of leading blood tests for Alzheimer's disease pathology","volume":"20","author":"Schindler SE","year":"2024","journal-title":"Alzheimers Dement"},{"key":"e_1_2_9_32_1","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1002\/alz.13764","article-title":"Clinical validation of the PrecivityAD2 blood test: a mass spectrometry\u2010based test with algorithm combining %p\u2010tau217 and A\u03b242\/40 ratio to identify presence of brain amyloid","volume":"20","author":"Meyer MR","year":"2024","journal-title":"Alzheimers Dement"},{"key":"e_1_2_9_33_1","doi-asserted-by":"crossref","first-page":"3990","DOI":"10.1007\/s00259-024-06835-2","article-title":"[18F]\u2010D3FSP \u03b2\u2010amyloid PET imaging in older adults and alzheimer's disease","volume":"51","author":"Li A","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"e_1_2_9_34_1","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2967\/jnumed.114.148981","article-title":"Measurement of longitudinal \u03b2\u2010amyloid change with 18 F\u2010Florbetapir PET and standardized uptake value ratios","volume":"56","author":"Landau SM","year":"2015","journal-title":"J Nucl Med"},{"key":"e_1_2_9_35_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v098.i11","article-title":"Cutpointr: improved estimation and validation of optimal cutpoints in R","volume":"98","author":"Thiele C","year":"2021","journal-title":"J Stat Softw"},{"key":"e_1_2_9_36_1","doi-asserted-by":"crossref","DOI":"10.1002\/alz.14609","article-title":"A head\u2010to\u2010head comparison of plasma biomarkers to detect Alzheimer's disease in a memory clinic","volume":"21","author":"Anastasi F","year":"2025","journal-title":"Alzheimers Dement"},{"key":"e_1_2_9_37_1","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1093\/brain\/awac333","article-title":"Head\u2010to\u2010head comparison of 10 plasma phospho\u2010tau assays in prodromal Alzheimer's disease","volume":"146","author":"Janelidze S","year":"2023","journal-title":"Brain"},{"key":"e_1_2_9_38_1","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70038","article-title":"Diagnostic accuracy of plasma p\u2010tau217\/A\u03b242 for Alzheimer's disease in clinical and community cohorts","volume":"21","author":"Wang J","year":"2025","journal-title":"Alzheimers Dement"},{"key":"e_1_2_9_39_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100472","article-title":"Association of plasma p\u2010tau and p\u2010tau\/a\u03b2 ratio with Alzheimer's pathology","volume":"13","author":"Chen X","year":"2026","journal-title":"J Prev Alzheimers Dis"},{"key":"e_1_2_9_40_1","doi-asserted-by":"crossref","first-page":"1168\u2013","DOI":"10.1093\/brain\/awag001","article-title":"Plasma pTau 217: \u03b2\u2010amyloid 1\u201042 ratio for enhanced accuracy and reduced uncertainty in detecting amyloid pathology","volume":"149","author":"Benina N","year":"2026","journal-title":"Brain"},{"key":"e_1_2_9_41_1","doi-asserted-by":"crossref","first-page":"6506","DOI":"10.1002\/alz.14140","article-title":"Optimizing cutpoints for clinical interpretation of brain amyloid status using plasma p\u2010tau217 immunoassays","volume":"20","author":"Figdore DJ","year":"2024","journal-title":"Alzheimers Dement"},{"key":"e_1_2_9_42_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105805","article-title":"Comparative performance of plasma pTau181\/A\u03b242, pTau217\/A\u03b242 ratios, and individual measurements in detecting brain amyloidosis","volume":"117","author":"Lehmann S","year":"2025","journal-title":"EBioMedicine"},{"key":"e_1_2_9_43_1","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41582-018-0079-7","article-title":"Blood\u2010based biomarkers for Alzheimer disease: mapping the road to the clinic","volume":"14","author":"Hampel H","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"e_1_2_9_44_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanhl.2024.07.013","article-title":"Challenges in the practical implementation of blood biomarkers for Alzheimer's disease","volume":"5","author":"Sch\u00f6ll M","year":"2024","journal-title":"Lancet Healthy Longev"},{"key":"e_1_2_9_45_1","doi-asserted-by":"crossref","DOI":"10.1002\/alz.14585","article-title":"Influence of cognitive impairment and race on plasma p\u2010Tau217 in two diverse cohorts","volume":"21","author":"Nayyar A","year":"2025","journal-title":"Alzheimers Dement"},{"key":"e_1_2_9_46_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100264","article-title":"A modelling approach to derive population\u2010specific cutoff for plasma p\u2010Tau217","volume":"12","author":"Liew TM","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"key":"e_1_2_9_47_1","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70463","article-title":"Impact of racialization on neuroimaging and plasma biomarkers of Alzheimer's disease","volume":"21","author":"Gogola A","year":"2025","journal-title":"Alzheimers Dement"}],"container-title":["Annals of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ana.78322","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ana.78322","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ana.78322","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T03:46:13Z","timestamp":1786765573000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ana.78322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":46,"alternative-id":["10.1002\/ana.78322"],"URL":"https:\/\/doi.org\/10.1002\/ana.78322","archive":["Portico"],"relation":{},"ISSN":["0364-5134","1531-8249"],"issn-type":[{"value":"0364-5134","type":"print"},{"value":"1531-8249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"assertion":[{"value":"2026-04-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"ana.78322"}}